Tarlatamab

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Metastatic/Locally Advanced Small-Cell Lung Cancer

Conditions

Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC, Metastatic/Locally Advanced High-grade MTC

Trial Timeline

Jul 2, 2025 → Jan 15, 2030

NCT ID

NCT07016230

About Tarlatamab

Tarlatamab is a phase 2 stage product being developed by Amgen for Metastatic/Locally Advanced Small-Cell Lung Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07016230. Target conditions include Metastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC, Metastatic/Locally Advanced High-grade MTC.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06064500	Pre-clinical	Completed	—	—	Small Cell Lung Cancer
NCT07203053	Phase 2	Recruiting	May 1, 2026	Oct 1, 2029	Extensive Stage Lung Small Cell Cancer
NCT07423585	Phase 2	Recruiting	Apr 1, 2026	Dec 31, 2027	Extensive Stage Lung Small Cell Carcinoma
NCT06814496	Phase 1/2	Recruiting	Sep 8, 2025	May 1, 2030	Melanoma
NCT06776250	Phase 2	Recruiting	Aug 18, 2025	Mar 3, 2028	Astrocytic Tumor
NCT07111507	Phase 2	Recruiting	Jul 31, 2025	Aug 31, 2027	Metastatic Prostate Cancer
NCT07016230	Phase 2	Recruiting	Jul 2, 2025	Jan 15, 2030	Metastatic/Locally Advanced Small-Cell Lung Cancer
NCT06816394	Phase 2	Recruiting	May 15, 2025	Apr 30, 2029	Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma
NCT06745323	Phase 2	Active	Feb 26, 2025	Feb 9, 2029	Small Cell Lung Cancer (SCLC)
NCT06598306	Phase 1	Recruiting	Oct 7, 2024	Mar 27, 2030	Extensive Stage Small Cell Lung Cancer
NCT06502977	Phase 2	Active	Aug 27, 2024	Jan 8, 2027	Extensive Stage Small Cell Lung Cancer
NCT05060016	Phase 2	Active	Dec 1, 2021	Dec 30, 2027	Relapsed/Refractory Small Cell Lung Cancer
NCT04702737	Phase 1	Completed	Jun 10, 2021	Jul 22, 2024	Neuroendocrine Prostate Cancer

Competing Products

1 competing product in Metastatic/Locally Advanced Small-Cell Lung Cancer

See all competitors

Product	Company	Stage	Hype Score
ASP3082	Astellas Pharma	Phase 2	52

Other Products from Amgen